Chronic inflammation, insulin resistance, psoriasis - which have in common?

Cover Page


Cite item

Full Text

Abstract

Psoriasis is recognized as system immune inflammatory disease at a certain genetic basis. It was found that psoriasis develops under the influence of chronic systemic inflammation low intensity (low grade inflammation) that induced insulin resistance, and is one of the clinical forms of the Immune Metabolic Disease (IMD), along with atherosclerosis, hypertension, type 2 diabetes, obesity and many other diseases, whose tight relationship with psoriasis are installed. Knowledge of the etiology, pathogenesis and molecular mechanisms of communication with other clinical forms of the IMD opens up new ways of prevention and treatment of psoriasis. Please note that other diseases associated with psoriasis, occurring hidden, often have greater predictive value for the life and health of the patient than mild or moderate forms of psoriasis, and be not limited to ascertaining the diagnosis and symptomatic treatment and actively participate in prevention. Debated question of the application of funds, suppressing systemic inflammation and insulin resistance in the treatment of psoriasis.

About the authors

M. S. Rasin

Ukrainian medical stomatological Academy

Author for correspondence.
Email: profrasin@gmail.com
Россия

References

  1. Siegel D., Devaraj S., Mitra A., Raychaudhuri S.P., Raychaudhuri S.K. and Jialal I. Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol 2013; 44: 194-204.
  2. Bremmer S., Van Voorhees A.S., Hsu S., Korman N.J., Lebwohl M.G., Young M., Bebo B.F., Jr. and Blauvelt A. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 63: 1058-69.
  3. Jensen P., Thyssen J.P., Zachariae C., Hansen P.R., Linneberg A. and Skov L. Cardiovascular risk factors in subjects with psoriasis: a cross-sectional general population study. Int J Dermatol 2013; 52: 681-3.
  4. Roberts K.K., A.E. Cocher, P.B. Lamb, P.J. Brown, D.F. Battafarano, E.M. Brunt, S.A. Harrison. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Alimentary Pharmacol Therap 2015; 41: 293-300.
  5. Moro F., De Simone C., Morciano A., Tropea A., Sagnella F., Palla C., Scarinci E., Teti A., Caldarola G., D'Agostino M., Mancuso S., Lanzone A., Apa R. Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis. Fertil Steril 2013; 99 (3): 936-42.
  6. Gero Kramer, Dieter Mitteregger and Michael Marberger. Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease? European Urology 2007; 51: 1202-1216.
  7. Tobin A.M., Veale D.J., Fitzgerald O., Rogers S., Collins P., O'Shea D. and Kirby B. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010; 37: 1386-94.
  8. Michelle A. Lowes, Mayte Suarez-Farinas, and James G. Krueger. Immunology of Psoriasis. Annual Review of Immunology 2014; 32: 227-255.
  9. Rui Tian, Gonglin Hou Dan Li, and Ti-Fei Yuan. A Possible Change Process of Inflammatory Cytokines in the Prolonged Chronic Stress and Its Ultimate Implications for Health. The Scientific World Journal. Volume 2014 (2014).
  10. Rui Tian, Gonglin Hou Dan Li, and Ti-Fei Yuan. A Possible Change Process of Inflammatory Cytokines in the Prolonged Chronic Stress and Its Ultimate Implications for Health. The Scientific World Journal. Volume 2014 (2014).
  11. Kajdashev I.P. NF-KB-signalizaciya kak osnova razvitiya sistemnogo vospaleniya, insulinorezistentnosti, lipotoksichnosti, saharnogo diabeta 2-go tipa i ateroskleroza. Mezhdunarodnyj ehndokrinologicheskij zhurnal 2011; 3 (35); 35-40.
  12. Rohleder N. Stimulation of systemic low-grade inflammation by psychosocial stress. Psychosom Med 2014; 76 (3): 181-9.
  13. Miller G.E., E. Chen, J. Sze et al., “A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kB signaling” Biological Psychiatry 2008; 64: 266-272.
  14. Selye H. “The general adaptation syndrome and the diseases of adaptation” Journal of Allergy 1946; 17: 358-398.
  15. Kadmiel M. and J.A. Cidlowski, “Glucocorticoid receptor signaling in health and disease” Trends in Pharmacological Sciences 2013; 34: 518-530.
  16. Segerstrom S.C. and G.E. Miller, “Psychological stress and the human immune system: a metaanalytic study of 30 years of inquiry,” Psychological Bulletin, vol. 130, no. 4, pp. 601-630, 2004.
  17. Miller G.E., Cohen S. and Ritchey A.K., “Chronic psychological stress and the regulation of pro-inflammatory cytokines: a glucocorticoid-resistance model,” Health Psychology 2002; 21: 531-541.
  18. Busillo J.M., K. M. Azzams, and J. A. Cidlowski, “Glucocorticoids sensitize the innate immune system through regulation of the NLRP3 inflamma-some,” The Journal of Biological Chemistry 2011; 286: 38703-38713.
  19. Ramamoorthy S. and J.A. Cidlowski, “Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance,” Endocrine Development, vol. 24, no. 41, p. 56, 2013.
  20. Selye H. "Confusion and controversy in the stress field". Journal of Human Stress 1975; 1 (2): 37-44.
  21. Calcagni E. and I. Elenkov, “Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases,” Annals of the New York Academy of Sciences 2006; 1069: 62-76.
  22. Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. Journal of leukocyte biology 2005; 78: 819-3.
  23. Bastard J-P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H. et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. European cytokine network 2006; 17: 4-12.
  24. Calder P.C., Kew S. The immune system: a target for functional foods? Brit J Nutr 2002; 88 Suppl 2: S165-77.
  25. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Brit J Nutr 2004; 92: 347-55.
  26. Salmeron J., Manson J.E., Stampfer M.J., Colditz G.A., Wing A.L., Willett W.C. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 1997; 277: 472-7.
  27. Wahli W., L. Michalik. PAППs at the crossroads of lipid signaling and inflammation. Trends in Endocrinology & Metabolism 2012; 23 (7): 351-363.
  28. Dasu, M.R. et al. Toll-like receptors and diabetes: a therapeutic perspective. Clin Sci 2012; 122: 203-214.
  29. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 2009; 49: 123-150.
  30. Dowlatshahi E.A., van der Voort E.A., Arends L.R., Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2013 Aug; 169 (2): 266-82.
  31. DeFronzo R., Tobin J., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214-223.
  32. Boehncke S., Thaci D., Beschmann H., Ludwig R.J., Ackermann H., Badenhoop K. and Boehncke W.H. Psoriasis patients show signs of insulin resistance. Br J Dermatol. 2007; 157: 1249-51.
  33. Nograles K.E., Zaba L.C., Shemer A. et al. (2009) IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 123: 1244-1252.
  34. Vinod Chandran. Genetics of psoriasis and psoriatic arthritis. Indian J dermat 2010; 55920: 151-156.
  35. Kolehmainen M., S. M. Ulven, J. Paananen, V. et al. Healthy Nordic diet downregulates the expression of genes involved in inflammation in subcutaneous adipose tissue in individuals with features of the metabolic syndrome. Am J Clin Nutr, 2014; 101 (1): 228.
  36. Won-Ha Leea,b,d, Tae-Hong Hwangb, Goo Taeg Ohc, Sung Uk Kwona, Yoon-Ho Choia and Jeong. Genetic factors associated with endothelial dysfunction affect the early onset of coronary artery disease in Korean males. Vascular Medicine 2001; 6: 103-108.
  37. Dongiovanni P, Anstee Q.M, and L. Valenti. Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment. CurrPharmDes 2013; 19(29): 5219-523.
  38. Glossmann H., Reider N. A marriage of two "Methusalem" drugs for the treatment of psoriasis? Arguments for a pilot trial with metformin as add-on for methotrexate. Dermatoendocrinol 2013; 5 (2): 252-63.
  39. Shafiq N., Malhotra S., Pandhi P., Gupta M., Kumar B., Sandhu K. Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 2005 Apr; 44 (4): 328-33.
  40. Deborah Brauser. Pioglitazone Combined With Acitretin Appears Safe, Effective for Moderate to Severe Chronic Plaque-Type Psoriasis. Arch Dermatol 2009; 145: 387-393.
  41. Hamminga E.A., van derLely A.J., Neumann H.A., Thio H.B. Chronic inflammation in psoriasis and obesity, implications for therapy. Med Hypotheses 2006; 67: 768-73.
  42. Benoit Viollet, Bruno Guigas, Nieves Sanz Garcia et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012 Mar; 122(6): 253-70.
  43. Schernthaner G., Craig J. Currie, Gerit-Holger Schernthaner. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care; 36 Suppl 2:S155-61.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Rasin M.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies